View source for AdCLD-CoV19

{{short description|Vaccine candidate against COVID-19}}
{{Use dmy dates|date=July 2021}}
{{Infobox drug
| Verifiedfields     =
| verifiedrevid      =
| drug_name          =
| INN                =
| type               = vaccine
| image              =
| alt                =
| caption            =
| target             = [[Severe acute respiratory syndrome coronavirus 2|SARS-CoV-2]]
| vaccine_type       = viral
<!-- Clinical data -->
| pronounce          =
| tradename          =
| Drugs.com          =
| MedlinePlus        =
| licence_EU         =
| licence_US         =
| pregnancy_AU       = <!-- A/B1/B2/B3/C/D/X -->
| pregnancy_category =
| legal_AU           = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU_comment   =
| legal_BR           = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->
| legal_BR_comment   =
| legal_CA           = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK           = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US           = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_UN           = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_NZ           = <!--Class A, B, C -->
| legal_status       =
| routes_of_administration = [[Intramuscular injection|Intramuscular]]
<!-- Identifiers -->
| CAS_number         = 2698316-99-1
| CAS_number_Ref     = <ref>{{cite web|url=https://www.wipo.int/edocs/pubdocs/en/wipo-pub-1075-en-covid-19-related-vaccines-and-therapeutics.pdf|title=Patent Landscape Report COVID-19-related vaccines and therapeutics}}</ref>
| ATCvet             =
| ATC_prefix         =
| ATC_suffix         =
| PubChem            =
| DrugBank           =
| synonyms           =
}}
{{COVID-19 pandemic sidebar}}

'''AdCLD-CoV19''' is a [[COVID-19 vaccine]] candidate developed by Cellid Co,<ref>{{cite news | vauthors = Chan-Hyuk K |title=LG Chem pushes for Covid-19 vaccine CMO deal |url=http://www.koreabiomed.com/news/articleView.html?idxno=9876 |access-date=22 August 2021 |publisher=[[Korea Biomedical Review]] |date=10 December 2020}}</ref><ref>{{cite news | vauthors = Chan-hyuk K |title=Covid-19 vaccine trials stalled by rare chance to get licensed vaccines |url=https://www.koreabiomed.com/news/articleView.html?idxno=11877 |access-date=22 August 2021 |publisher=[[Korea Biomedical Review]] |date=11 August 2021}}</ref> a company from South Korea.<ref>{{cite web | url = https://www.bloomberg.com/profile/company/299660:KS | title = Cellid Co Ltd, Company Profile and News | work = Bloomberg Markets }}</ref>

A phase 1/2 trial of a single injection of AdCLD-CoV19 began in December 2020 in South Korea.<ref name="Trial registration NCT04666012">{{ClinicalTrialsGov|NCT04666012|Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers}}</ref> In September 2021, a phase 1 trial began for a single injection of another version, named AdCLD-CoV19-1.<ref name="Trial registration NCT05047692">{{cite web |last1=Cellid Co |title=A Dose Escalation, Multicenter, Open, Phase I Study to Assess the Safety and Immunogenicity of AdCLD-CoV19-1, a COVID-19 Preventive Vaccine in Healthy Volunteers. |url=https://clinicaltrials.gov/ct2/show/NCT05047692 |website=clinicaltrials.gov |publisher=National Institutes of Health |access-date=27 September 2022 |date=21 January 2022}}</ref>
Preclinical studies of a single dose in mice and non-human primates for this vaccine candidate were published in April 2022.<ref name="Preclinical 2022">{{cite journal | vauthors = Shin SP, Shin KS, Lee JM, Jung IK, Koo J, Lee SW, Park S, Shin J, Park M, Park B, Oh H, Koo BS, Hong J, Ryu CM, Kim JO, Oh T, Kang CY | display-authors = 6 | title = The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates | journal = Vaccines | volume = 10 | issue = 5 | pages = 712 | date = April 2022 | pmid = 35632468 | pmc = 9147121 | doi = 10.3390/vaccines10050712 | doi-access = free }}</ref> In August 2022, a phase 2 trial of 1 or 2 doses of AdCLD-CoV19-1 was registered.<ref name="Registration phase 2 trial NCT05520970">{{cite journal |last1=Cellid Co |title=A Phase IIb, Multicenter, Observer-Blinded, Randomized, Placebo-Controlled Trial to Evaluate the Immunogenicity and Safety of the AdCLD-CoV19-1 in Healthy Adults Aged 19 Years Old and Above |url=https://clinicaltrials.gov/ct2/show/NCT05520970 |website=clinicaltrials.gov |publisher=National Institutes of Health |access-date=27 September 2022 |date=27 August 2022}}</ref>

== References ==
{{reflist}}

{{scholia}}

{{Vaccines}}
{{COVID-19 pandemic}}
{{Portal bar | Medicine | Viruses | COVID-19}}

[[Category:Clinical trials related to COVID-19]]
[[Category:South Korean COVID-19 vaccines]]
[[Category:Science and technology in South Korea]]
[[Category:Viral vector vaccines]]

{{COVID19-vaccine-stub}}
{{Vaccine-stub}}